Espanõl

Print Article
Email Article

Share

Cancer Resources > Cancer News > Cancer News from Reuters > Reuters Cancer News > 2005 > April

Longer screening intervals delay prostate cancer detection

Will Boggs, MD

Last Updated: 2005-04-28 10:31:10 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Extending the prostate cancer screening interval to 2 or 4 years would substantially delay the detection of advanced prostate cancers, according to a report in the April issue of The Journal of Urology.

"Even though a relatively small percentage of men have rapidly rising PSA levels, they are the ones with life-threatening prostate cancer," Dr. William J. Catalona from Northwestern University, Chicago, told Reuters Health. "The widespread use of infrequent screening intervals could lead to delays in the detection of these potentially lethal cancers until the opportunity for cure is missed."

Dr. Catalona and colleagues used data from more than 18,000 men screened for prostate cancer at 6-month to 1-year intervals to determine the potential delay in detection that could result from 2- and 4-year PSA screening intervals.

A total of 377 (2.0%) of the subjects had prostate cancer diagnosed over 8 years of follow-up. Only 24% of the 1569 men who underwent biopsy were found to have prostate cancer, the results indicate.

PSA level at the time of prostate cancer detection was less than 2.6 ng/mL in 21% of men, 2.6 to 4.0 ng/mL in 57% of men, and over 4.0 ng/mL in only 20% of men, the authors report.

Increasing the screening interval from 1 year to 2 years would have resulted in at least a 4-month delay in prostate cancer detection in 62% of the men, the researchers note. More than three quarters of the men (77%) would have experienced a mean delay of detection of 12 months were the screening interval extended to 4 years.

"Many of these diagnosed tumors had potentially aggressive histological phenotypes," the investigators write. "Infrequent screening may also delay the detection of prostate cancer in men with rapidly increasing PSA, who most likely would benefit from early diagnosis."

"We are monitoring my various databases for the possible effects of delayed diagnosis on relevant outcomes, such as progression-free survival, metastases-free survival, cancer-specific survival, and overall survival," Dr. Catalona said.

"Further careful study is indicated before recommending screening intervals longer than 1 year," he concluded.

J Urol 2005;173:1116-1120.

Copyright © 2009 Reuters Limited. All rights reserved.
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.